echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > MSD's $375 million acquisition of oncoethix to further expand oncology assets

    MSD's $375 million acquisition of oncoethix to further expand oncology assets

    • Last Update: 2014-12-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Biovalley December 19, 2014 Merck & Co recently announced the acquisition of oncoethix, a Swiss biotechnology company, for us $375 million This is another move of Merck & Co to continuously strengthen its oncology pipeline to enter the oncology market Oncoethix specializes in the research and development of new drugs in the field of oncology, which is one of the major growth areas that mosadon focuses on Under the terms of the deal, MSD will pay $110 million in upfront payments and oncoethix will be eligible for milestone payments of up to $265 million Through this acquisition, mosadon obtained the experimental drug otx015 of oncoethix company, which is a bet (bromer domain) inhibitor, aiming to trigger cancer cell death by targeting the protein 2 / 3 / 4 of the bet bromer domain At present, otx015 is in stage IB clinical development for the treatment of advanced solid tumors Bet inhibitors have the potential to treat a wide range of tumor types Otx015 is the first bet inhibitor with the potential to block myc protein, which is responsible for regulating the transcription of growth promoting genes and cell cycle regulators Myc blocking has shown therapeutic potential for a variety of blood cancers, including acute myeloid leukemia, Burkitt lymphoma and multiple myeloma At present, expanding pipeline assets through small-scale transactions has become a common trick used by pharmaceutical giants to strengthen key R & D areas And MSD is building assets around keytruda, the PD-1 tumor immunotherapy, and is also looking for potential new combination therapies Therefore, otx015 is very suitable for mossadon's strategic blueprint of oncology PD-1 / PD-L1 immunotherapy is a new kind of anti-cancer immunotherapy, which aims to use the immune system of human body to resist cancer, and has the potential to treat many types of tumor At present, PD-1 / PD-L1 immune competition is extremely fierce, with a market value of US $35 billion The competition in this field has gradually expanded from melanoma to breast cancer, lung cancer and blood cancer According to data released earlier this month, keysruda has shown good therapeutic potential for three negative breast cancer and Hodgkin's lymphoma (HL) (related reading: keysruda, the PD-1 immunotherapy of MSD, shows the therapeutic potential of three negative breast cancer (TNBC); the total remission rate of the PD-1 inhibitor keysruda in treating blood cancer is 66) On the other hand, various giants are also cooperating in succession to investigate the combination therapy of PD-1 inhibitor and other drugs, so as to thoroughly explore the maximum clinical potential of this kind of drugs Last week, MSD teamed up with Amgen to investigate the use of keytruda / t-vec, a cancer immune cocktail, in the treatment of melanoma In fact, as early as 2013, MSD announced a strategy to narrow its business to focus areas, including acute hospitalization, vaccines and oncology The company has made it clear that it is not keen to pursue large-scale acquisitions, but rather tends to pursue small and medium-sized acquisitions to strengthen its R & D pipeline and product portfolio At the beginning of this month, MSD spent $9.5 billion to buy cupist, an antibiotic giant The move will give the company a better position in the field of hospital emergency care and will address unmet medical needs in key areas, such as antibiotic resistance, mosadon said.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.